Xilio Therapeutics reports $121.6mln cash, Q2 pipeline progress.

• Xilio Therapeutics announced updated Phase 2 data for vilastobart, an anti-CTLA-4 combination therapy. • Vilastobart demonstrated deep and durable responses with a safe and tolerable profile. • Xilio is on track to nominate first development candidates for masked T cell engager programs in H2 2025. • The company has $121.6 million in cash and cash equivalents, with a cash runway through Q3 2026.

Waltham, Mass., July 2, 2025 — Xilio Therapeutics, Inc. (NASDAQ: XLO) has announced updated Phase 2 data for vilastobart, an anti-CTLA-4 combination therapy, demonstrating deep and durable responses with a safe and tolerable profile. The company also reported significant financial milestones, including $121.6 million in cash and cash equivalents as of June 30, 2025, extending its cash runway through the end of the third quarter of 2026 [1].

Clinical Progress with Vilastobart

Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody, showed a 26% objective response rate in metastatic microsatellite stable colorectal cancer patients without liver metastases. The therapy demonstrated deep, durable responses and a differentiated safety profile, providing an impressive clinical achievement in a notoriously difficult-to-treat population. The combination therapy with atezolizumab (Tecentriq®) showed promising results, highlighting the significant opportunity for vilastobart across various indications and tumor types [1].

Pipeline Advancements and Financial Highlights

Xilio is on track to nominate first development candidates for its masked T cell engager programs in the second half of 2025. The company's pipeline includes XTX301, a tumor-activated IL-12 program in partnership with Gilead, and XTX501, a masked PD-1/IL-2 bispecific, which is advancing toward IND submission by mid-2026. Additionally, Xilio has an emerging portfolio of masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1, with development candidates expected in the third and fourth quarters of 2025 [1].

Financial Position and Cash Runway

As of June 30, 2025, Xilio reported $121.6 million in cash and cash equivalents, up from $55.3 million at the end of 2024. This financial strength is bolstered by a $50.0 million follow-on offering in June 2025, with potential for additional $100.0 million from warrant exercises. The company expects to fund its operations and capital expenditure requirements through the end of the third quarter of 2026 [1].

Conclusion

Xilio Therapeutics' Q2 results reveal significant progress across its innovative tumor-activated immunotherapy pipeline, with vilastobart emerging as a standout program. The company's financial position and pipeline advancements position it well for future growth and development. Investors and financial professionals should closely monitor Xilio's progress as it continues to advance its pipeline and secure its financial runway.

References

[1] https://www.stocktitan.net/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-bbyate5esg93.html